Gilead to charge governments $2,340 per patient for remdesivir
US secures over 500,000 treatment courses for the next three months
29 June 2020 - 20:13
Gilead Sciences has priced its Covid-19 drug candidate remdesivir at $2,340 for a five-day treatment in the US and some other developed countries, potentially reflecting looming competition from a cheap steroid.
The price tag is below the $5,080 per course recommendation by US drug pricing research group, the Institute for Clinical and Economic Review (ICER), last week...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.